ACE and Hypokalemia: The prevalence was more likely to be higher in patient populations that were studied before the introduction of beta-blockers, ACE-inhibitors, and AT1-antagonists as standard HF therapy, as all of these drugs increase serum K+ levels and thus counteract hypokalemia.